NAMS Menopause Certification Exam
2026/2027 | Newly Released| Latest Update
100 Questions with Verified Answers & Rationales
Graded A+| 100% Correct | Guaranteed Pass
Q1: Denosumab is a pharmacologic agent used for the treatment of postmenopausal
osteoporosis. What is its primary mechanism of action?
A. Directly stimulating osteoblast activity to increase bone formation
B. Binding to and inhibiting RANKL, thereby preventing osteoclast maturation and
survival [CORRECT]
C. Mimicking the action of parathyroid hormone to stimulate bone turnover
D. Acting as a selective estrogen receptor modulator to preserve bone density
Correct Answer: B
Rationale: Denosumab is a monoclonal antibody that targets and binds to RANKL (Receptor
Activator of Nuclear factor Kappa-B Ligand), preventing it from interacting with its receptor on
osteoclast precursors. Correct because this inhibition stops osteoclast maturation and survival,
effectively reducing bone resorption and increasing bone mineral density.
Q2: A 55-year-old woman presents with a history of a deep vein thrombosis (DVT) three years
ago following a long-haul flight. She is experiencing severe vasomotor symptoms that
significantly impair her quality of life. Which of the following is the most appropriate
menopause hormone therapy (MHT) regimen for this patient?
A. Oral conjugated equine estrogens with micronized progesterone
B. Transdermal estradiol with micronized progesterone [CORRECT]
C. Oral estradiol with medroxyprogesterone acetate
D. High-dose transdermal estradiol alone
Correct Answer: B
Rationale: For a woman with a history of VTE requiring MHT for severe VMS, transdermal
estrogen bypasses first-pass hepatic metabolism, thereby avoiding the hepatic induction of
clotting factors and offering a lower VTE risk compared to oral estrogen. Per NAMS guid elines,
micronized progesterone is preferred over synthetic progestins as it does not appear to attenuate
the favorable lipid profile or increase VTE risk associated with transdermal estradiol.
,Q3: When interpreting the Women's Health Initiative (WHI) findings for clinical practice, which
of the following statements reflects the current evidence-based understanding?
A. The WHI proved that all types of MHT increase cardiovascular disease risk equally in all
women
B. The timing hypothesis explains that initiation of MHT in younger women closer
to menopause onset may confer cardiovascular benefits or be neutral [CORRECT]
C. The WHI demonstrated that estrogen alone increases breast cancer risk significantly
D. The WHI data should be directly extrapolated to women in their late 40s and early 50s
Correct Answer: B
Rationale: Per the timing hypothesis, often referred to as the "age and time" rule, initiation of
MHT within 10 years of menopause onset or before age 60 may provide cardiovascular benefits
or be neutral, whereas initiation later in life may increase risk. The WHI studied older women
(mean age 63) and found that estrogen alone actually decreased breast cancer risk, making the
other options incorrect.
Q4: The luteal out-of-phase (LOOP) event is a hormonal phenomenon observed during the
menopause transition. What is its primary pathophysiological characteristic?
A. Elevated progesterone levels during the early follicular phase
B. A rise in estradiol without a preceding LH surge
C. Secretion of progesterone from an ovary that did not ovulate, occurring out of
synchrony with the typical luteal phase [CORRECT]
D. Suppression of FSH by abnormally high inhibin B levels
Correct Answer: C
Rationale: The LOOP phenomenon occurs when a follicle produces progesterone without prior
ovulation, leading to elevated progesterone levels at an unexpected time in the menstrual cycle.
Correct because this aberrant progesterone secretion explains some of the unpredictable
bleeding patterns and cycle irregularities characteristic of the late menopausal transition.
,Q5: A 51-year-old woman with an intact uterus is prescribed oral estradiol 1 mg daily for
moderate-to-severe vasomotor symptoms. Which progestogen regimen is most appropriate to
protect her endometrium while minimizing adverse metabolic effects?
A. Micronized progesterone 100 mg daily continuously [CORRECT]
B. Medroxyprogesterone acetate 10 mg for 10 days every 3 months
C. Norethindrone acetate 0.35 mg daily continuously
D. Levonorgestrel-releasing intrauterine device
Correct Answer: A
Rationale: For a woman with an intact uterus requiring systemic estrogen, micronized
progesterone 100 mg daily continuously is a highly effective regimen for endometrial protection.
According to NAMS guidelines, micronized progesterone is preferred over synthetic progestins
like MPA because it has a more neutral effect on lipid profiles, blood pressure, and
cardiovascular risk markers.
Q6: Anti-Müllerian hormone (AMH) is widely used as a biomarker in the assessment of ovarian
aging. Which statement accurately describes AMH in the context of the menopause transition?
A. AMH is secreted by the pituitary gland in response to declining estradiol
B. AMH levels remain stable until the final menstrual period and then drop abruptly
C. AMH is produced by granulosa cells of growing ovarian follicles and declines
progressively as the ovarian reserve diminishes [CORRECT]
D. AMH is the primary driver of vasomotor symptoms during the late menopausal transition
Correct Answer: C
Rationale: AMH is produced by the granulosa cells of small growing follicles and serves as a
direct marker of ovarian reserve, declining progressively until it becomes undetectable at the
time of menopause. Correct because unlike FSH, which fluctuates cycle-to-cycle, AMH provides
a reliable, cycle-independent indicator of the ovarian follicular depletion mechanism.
, Q7: A 62-year-old woman presents with severe dyspareunia and vaginal dryness. She has a
history of estrogen receptor-positive breast cancer treated with lumpectomy and radiation 5
years ago. Her oncologist has advised against systemic or local vaginal estrogen. Which non-
hormonal prescription medication is most appropriate for her Genitourinary Syndrome of
Menopause (GSM)?
A. Ospemifene
B. Vaginal dehydroepiandrosterone (DHEA)
C. Oral conjugated equine estrogens
D. Vaginal moisturizers and lubricants as first-line management [CORRECT]
Correct Answer: D
Rationale: For a woman with a history of ER+ breast cancer where estrogen and selective
estrogen receptor modulators (like ospemifene) are contraindicated, non-hormonal therapies
are the mainstay of GSM management. Vaginal moisturizers (used regularly) and lubricants
(used at time of intercourse) are the correct initial prescription to improve vaginal tissue
elasticity and decrease friction-related dyspareunia.
Q8: A 58-year-old postmenopausal woman undergoes her first DEXA scan. Her T-score at the
total hip is -2.0, and her T-score at the lumbar spine is -2.5. Which FRAX-based clinical
intervention threshold is most appropriate according to current osteoporosis management
guidelines?
A. Pharmacologic treatment is indicated only if a fragility fracture has already occurred
B. Pharmacologic treatment is indicated because the lumbar spine T-score meets
the definition of osteoporosis [CORRECT]
C. Pharmacologic treatment is not indicated until the T-score reaches -3.0 or lower
D. Lifestyle modifications alone are sufficient since the hip T-score is only osteopenia
Correct Answer: B
Rationale: A T-score of -2.5 or lower at any skeletal site (in this case, the lumbar spine) meets
the diagnostic criteria for osteoporosis, independently mandating consideration of
pharmacologic treatment. Correct because the presence of osteoporosis by DEXA criteria alone
is an established indication for fracture prevention therapy, regardless of FRAX score or hip T-
score.
2026/2027 | Newly Released| Latest Update
100 Questions with Verified Answers & Rationales
Graded A+| 100% Correct | Guaranteed Pass
Q1: Denosumab is a pharmacologic agent used for the treatment of postmenopausal
osteoporosis. What is its primary mechanism of action?
A. Directly stimulating osteoblast activity to increase bone formation
B. Binding to and inhibiting RANKL, thereby preventing osteoclast maturation and
survival [CORRECT]
C. Mimicking the action of parathyroid hormone to stimulate bone turnover
D. Acting as a selective estrogen receptor modulator to preserve bone density
Correct Answer: B
Rationale: Denosumab is a monoclonal antibody that targets and binds to RANKL (Receptor
Activator of Nuclear factor Kappa-B Ligand), preventing it from interacting with its receptor on
osteoclast precursors. Correct because this inhibition stops osteoclast maturation and survival,
effectively reducing bone resorption and increasing bone mineral density.
Q2: A 55-year-old woman presents with a history of a deep vein thrombosis (DVT) three years
ago following a long-haul flight. She is experiencing severe vasomotor symptoms that
significantly impair her quality of life. Which of the following is the most appropriate
menopause hormone therapy (MHT) regimen for this patient?
A. Oral conjugated equine estrogens with micronized progesterone
B. Transdermal estradiol with micronized progesterone [CORRECT]
C. Oral estradiol with medroxyprogesterone acetate
D. High-dose transdermal estradiol alone
Correct Answer: B
Rationale: For a woman with a history of VTE requiring MHT for severe VMS, transdermal
estrogen bypasses first-pass hepatic metabolism, thereby avoiding the hepatic induction of
clotting factors and offering a lower VTE risk compared to oral estrogen. Per NAMS guid elines,
micronized progesterone is preferred over synthetic progestins as it does not appear to attenuate
the favorable lipid profile or increase VTE risk associated with transdermal estradiol.
,Q3: When interpreting the Women's Health Initiative (WHI) findings for clinical practice, which
of the following statements reflects the current evidence-based understanding?
A. The WHI proved that all types of MHT increase cardiovascular disease risk equally in all
women
B. The timing hypothesis explains that initiation of MHT in younger women closer
to menopause onset may confer cardiovascular benefits or be neutral [CORRECT]
C. The WHI demonstrated that estrogen alone increases breast cancer risk significantly
D. The WHI data should be directly extrapolated to women in their late 40s and early 50s
Correct Answer: B
Rationale: Per the timing hypothesis, often referred to as the "age and time" rule, initiation of
MHT within 10 years of menopause onset or before age 60 may provide cardiovascular benefits
or be neutral, whereas initiation later in life may increase risk. The WHI studied older women
(mean age 63) and found that estrogen alone actually decreased breast cancer risk, making the
other options incorrect.
Q4: The luteal out-of-phase (LOOP) event is a hormonal phenomenon observed during the
menopause transition. What is its primary pathophysiological characteristic?
A. Elevated progesterone levels during the early follicular phase
B. A rise in estradiol without a preceding LH surge
C. Secretion of progesterone from an ovary that did not ovulate, occurring out of
synchrony with the typical luteal phase [CORRECT]
D. Suppression of FSH by abnormally high inhibin B levels
Correct Answer: C
Rationale: The LOOP phenomenon occurs when a follicle produces progesterone without prior
ovulation, leading to elevated progesterone levels at an unexpected time in the menstrual cycle.
Correct because this aberrant progesterone secretion explains some of the unpredictable
bleeding patterns and cycle irregularities characteristic of the late menopausal transition.
,Q5: A 51-year-old woman with an intact uterus is prescribed oral estradiol 1 mg daily for
moderate-to-severe vasomotor symptoms. Which progestogen regimen is most appropriate to
protect her endometrium while minimizing adverse metabolic effects?
A. Micronized progesterone 100 mg daily continuously [CORRECT]
B. Medroxyprogesterone acetate 10 mg for 10 days every 3 months
C. Norethindrone acetate 0.35 mg daily continuously
D. Levonorgestrel-releasing intrauterine device
Correct Answer: A
Rationale: For a woman with an intact uterus requiring systemic estrogen, micronized
progesterone 100 mg daily continuously is a highly effective regimen for endometrial protection.
According to NAMS guidelines, micronized progesterone is preferred over synthetic progestins
like MPA because it has a more neutral effect on lipid profiles, blood pressure, and
cardiovascular risk markers.
Q6: Anti-Müllerian hormone (AMH) is widely used as a biomarker in the assessment of ovarian
aging. Which statement accurately describes AMH in the context of the menopause transition?
A. AMH is secreted by the pituitary gland in response to declining estradiol
B. AMH levels remain stable until the final menstrual period and then drop abruptly
C. AMH is produced by granulosa cells of growing ovarian follicles and declines
progressively as the ovarian reserve diminishes [CORRECT]
D. AMH is the primary driver of vasomotor symptoms during the late menopausal transition
Correct Answer: C
Rationale: AMH is produced by the granulosa cells of small growing follicles and serves as a
direct marker of ovarian reserve, declining progressively until it becomes undetectable at the
time of menopause. Correct because unlike FSH, which fluctuates cycle-to-cycle, AMH provides
a reliable, cycle-independent indicator of the ovarian follicular depletion mechanism.
, Q7: A 62-year-old woman presents with severe dyspareunia and vaginal dryness. She has a
history of estrogen receptor-positive breast cancer treated with lumpectomy and radiation 5
years ago. Her oncologist has advised against systemic or local vaginal estrogen. Which non-
hormonal prescription medication is most appropriate for her Genitourinary Syndrome of
Menopause (GSM)?
A. Ospemifene
B. Vaginal dehydroepiandrosterone (DHEA)
C. Oral conjugated equine estrogens
D. Vaginal moisturizers and lubricants as first-line management [CORRECT]
Correct Answer: D
Rationale: For a woman with a history of ER+ breast cancer where estrogen and selective
estrogen receptor modulators (like ospemifene) are contraindicated, non-hormonal therapies
are the mainstay of GSM management. Vaginal moisturizers (used regularly) and lubricants
(used at time of intercourse) are the correct initial prescription to improve vaginal tissue
elasticity and decrease friction-related dyspareunia.
Q8: A 58-year-old postmenopausal woman undergoes her first DEXA scan. Her T-score at the
total hip is -2.0, and her T-score at the lumbar spine is -2.5. Which FRAX-based clinical
intervention threshold is most appropriate according to current osteoporosis management
guidelines?
A. Pharmacologic treatment is indicated only if a fragility fracture has already occurred
B. Pharmacologic treatment is indicated because the lumbar spine T-score meets
the definition of osteoporosis [CORRECT]
C. Pharmacologic treatment is not indicated until the T-score reaches -3.0 or lower
D. Lifestyle modifications alone are sufficient since the hip T-score is only osteopenia
Correct Answer: B
Rationale: A T-score of -2.5 or lower at any skeletal site (in this case, the lumbar spine) meets
the diagnostic criteria for osteoporosis, independently mandating consideration of
pharmacologic treatment. Correct because the presence of osteoporosis by DEXA criteria alone
is an established indication for fracture prevention therapy, regardless of FRAX score or hip T-
score.
